Latest news

• Gilead gets OK for three-in-one hep C therapy in US

  The approval is believed to be the first for voxilaprevir anywhere in the world. ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.

• Samsung Bioepis wins CHMP nod for second Humira biosimilar

  virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir).

• Two new hepatitis C therapies fast-tracked in Europe

  EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve

• Gilead files hepatitis C salvage regimen in US

  Seeks FDA approval for combination of Epclusa and voxilaprevir. The new generation of directly-acting antiviral (DAAs) have transformed the treatment of hepatitis C virus (HCV) infections - but not all patients ... inhibitor called voxilaprevir.

• Gilead’s hepatitis C sales start to slide – the question is how quickly?

  well as a triplet therapy based on sofosbuvir, velpatasvir and voxilaprevir that is in four late-stage trials.